Company intelligence / Profile preview

SynthRx

San Francisco, California, United States

Ownership: Private
Employees: ~25
Development stage: Other

Overview

SyntheX has developed and validated a cell-based screening drug discovery platform focused on finding selective disruptors of protein-protein interactions in oncology. Early results suggest the platform can discover compounds that target DNA damage repair and other "undruggable" mechanisms; clinical programs in humans not yet announced.

Therapeutic areas: OncologyRare Diseases
Modalities: Small moleculePeptidesMacrocycles
Industry: Biotech

Partnerships

Bristol Myers SquibbJLabsIndieBio

Beyond the preview

Go deeper on SynthRx.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SynthRx.

Explore the full profile